Investigation Launched into Voyager Therapeutics, Inc. over Potential Securities Law Violations
New York, NY – February 24, 2025
Levi & Korsinsky, a leading securities law firm, has initiated an investigation into Voyager Therapeutics, Inc. (NASDAQ: VYGR) following the biotech company’s announcement on February 11, 2025, regarding its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).
Background
In the press release, Voyager Therapeutics disclosed that it had decided to assess alternate payloads for its SOD1 ALS gene therapy program due to emerging preclinical data indicating the siRNA payload component of VY9323, their lead product candidate, did not meet their high standards. The company stated that what appeared to be an off-target effect had resulted in a narrowed therapeutic window.
Impact on Voyager Therapeutics and the Biotech Industry
The announcement sent shockwaves through the biotech industry, causing Voyager Therapeutics’ stock price to plummet by more than 40% in the following days. The revelation of potential issues with the efficacy and safety of VY9323, a promising treatment for a debilitating neurodegenerative disease, has raised concerns about the company’s research and development capabilities.
Investigative Process
Levi & Korsinsky is investigating potential securities laws violations, specifically focusing on whether Voyager Therapeutics and its management team made false and/or misleading statements and failed to disclose material information to investors.
Implications for Investors
If you are a Voyager Therapeutics investor or held a position in VYGR securities between February 11, 2021, and the present, you may be entitled to compensation. Levi & Korsinsky encourages investors to contact the firm to discuss their potential remedies.
Global Repercussions
The investigation and its consequences extend beyond Voyager Therapeutics, potentially impacting the entire biotech sector. The incident serves as a reminder of the importance of transparency and thorough research in the development of new treatments, especially those aimed at complex and devastating diseases like ALS.
- Investors in Voyager Therapeutics may be entitled to compensation.
- The investigation highlights the importance of transparency and thorough research in the biotech industry.
- The incident may lead to increased scrutiny of other companies in the sector.
Conclusion
The investigation into Voyager Therapeutics by Levi & Korsinsky is a significant development for the biotech sector, with far-reaching implications for both the company and its investors. As the investigation progresses, it is crucial for all stakeholders to remain informed and vigilant, ensuring that the pursuit of life-changing treatments does not come at the expense of transparency and accountability.
For more information, please contact Levi & Korsinsky at 212-363-7500. The firm’s securities attorneys have extensive experience in prosecuting securities class actions and derivative actions on behalf of institutional and individual investors.
